Biovivium Strategies’ Post

📰 Read about #Ariceum’s new findings presented at #AACR2024 on the discovery of novel macrocyclic peptide #radioligands for tumor therapy by mRNA display in Drug Discovery World's (DDW) Summer issue 2024! Ariceum's Head of Translational Biology and Non-Clinical Pharmacology, Anika Jäkel spoke with DDW's, Megan Thomas to discuss the 'truly diverse' agenda at AACR which covered 'many forms of therapeutic approaches, with some revelatory findings about new biomarkers that could lead to a new generation of personalised therapies.' Check out the article here ▶ https://lnkd.in/gtSZijU9 #lifesciences #biotech #radiopharmaceuticals #ATT001 #ATT002 #satoreotide

Tomorrow, Halia’s CEO David Bearss Ph.D., will take part in Scintillant Bioscience virtual panel to discuss: “Visualizing the Present and Future: Imaging 2D Cell Culture and 3D Organoids for Therapeutics Discovery.” He will be joined by Russ Teichert, MBA, PhD, Founder and CEO of Scintillant Bioscience, Beth Hoffman, Ph.D., CEO of Origami Therapeutics, and Andrea Mazzocchi, Ph.D., VP of Partnerships at Pathos. The event will be held at 4:00p.m. (EST) To register for the event, visit the LinkedIn event page: https://lnkd.in/ezAJdQDj Talking Therapeutics is a Scintillant Bioscience initiative that aims to bridge the gap between laboratory research and clinical outcomes. This virtual series assembles a panel of industry experts, researchers, and clinicians to discuss emerging trends, share insights, and tackle the most pressing challenges in therapeutics discovery and development today. #inflammasome #chronicinflammation #NLRP3 #therapeutics

We're proud to welcome two bright minds to our team: both Dr. Madhurima Sarkar (PhD) end Dr. Upma Dave joined Hyloris in August, taking up the role of #scientific #affairs associate. They bring years of experience to help us grow our pipeline of #repurposed and #reformulated drug product candidates by scientifically evaluating projects and potential partners. 👋 Dr. Madhurima Sarkar (PhD) holds a doctorate degree in cancer biology and has experience in translational research. 👋 Dr. Upma Dave specialized in neurodegenerative disease pathway analysis for her PhD and has previous experience in computational drug screening. #hyloris #pharmaceuticals #repurposing #reformulation #505b2

𝗡𝗲𝘄 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗣𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 I am delighted to share our latest publication, "Prediction of Threonine-Tyrosine Kinase Receptor-Ligand Unbinding Kinetics with Multiscale Milestoning and Metadynamics." Access the full paper here: https://lnkd.in/ea8C_aH7 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝙄𝙣𝙣𝙤𝙫𝙖𝙩𝙞𝙫𝙚 𝘼𝙥𝙥𝙧𝙤𝙖𝙘𝙝 - We enhanced our existing Simulation-Enabled Estimation of Kinetics Rates (SEEKR) approach by integrating metadynamics (metaD) simulations to predict drug residence times for threonine-tyrosine kinase (TTK) inhibitors. 𝘼𝙘𝙘𝙪𝙧𝙖𝙩𝙚 𝙋𝙧𝙚𝙙𝙞𝙘𝙩𝙞𝙤𝙣𝙨 - Our method accurately predicts absolute and rank-ordered ligand residence times and binding free energies for eight long-residence-time inhibitors, essential for drug development strategies. 𝙀𝙣𝙝𝙖𝙣𝙘𝙚𝙙 𝙎𝙖𝙢𝙥𝙡𝙞𝙣𝙜 - By comparing steered molecular dynamics (SMD) and metadynamics (metaD) simulations, we demonstrated that metaD provides superior simulation initial structures, leading to better convergence and more accurate results. 𝘽𝙧𝙤𝙖𝙙 𝙄𝙢𝙥𝙡𝙞𝙘𝙖𝙩𝙞𝙤𝙣𝙨 - This work advances the understanding of TTK inhibitors, a promising target for breast cancer treatment, and sets a new benchmark for computational predictions of protein-ligand interactions. 𝙆𝙞𝙣𝙚𝙩𝙞𝙘 𝙋𝙖𝙧𝙖𝙢𝙚𝙩𝙚𝙧𝙨 - metaD within SEEKR produced better unbinding rate constants than traditional SMD, showing significant improvement in accuracy and reliability. 𝘽𝙞𝙣𝙙𝙞𝙣𝙜 𝙁𝙧𝙚𝙚 𝙀𝙣𝙚𝙧𝙜𝙮 Our approach resulted in a precise ranking of absolute unbinding kinetics, a notable achievement in the field. 𝙊𝙥𝙚𝙣 𝙎𝙤𝙪𝙧𝙘𝙚 𝙏𝙤𝙤𝙡𝙨 - SEEKR2 and SEEKRTOOLS are available on GitHub (https://lnkd.in/eriFhpf5), enabling broader adoption and further research advancements. Our work integrates advanced computational methods to enhance drug discovery and development. Great work from the SEEKR team, especially Lane Votapka and an incredible mentorship from Rommie. Excited to see where this leads next. #drugkinetics #drugdiscovery #cancerresearch #Metadynamics #SEEKR #moleculardynamics #residencetimes

We are breaking boundaries in the field of radiopharma! Radiopharmaceuticals minimizes off-target effects and maximizes the efficacy of treatment. Our team at Institute of Biotechnology, NTNU, PET-center at St. Olav Hospital and NTNU Technology Transfer AS in collaboration with Pharmatest, Finland, are thrilled to announce a groundbreaking innovation for the benefit of cancer patients. What is new?? To this date, an efficient and stable chelator for radium has not been identified. Our early results show our novel alginate-based nanoparticle has the ability to bind radium in vitro and is stable in serum. The development of a novel alginate based nanoparticle technology poised to offer the possibility to target 223Radium (or 224Ra) outside skeleton. But wait, there's more! Our nanoparticle also incorporates diagnostic capabilities, allowing for real-time monitoring of treatment response and disease progression using cupper isotopes such as 64Cu. This integration of therapy and diagnostics, known as theranostics, represents a paradigm shift in personalized medicine. Our work aims to translating cutting-edge research into tangible benefits for cancer patients worldwide. With its potential to enhance treatment outcomes, minimize side effects, and improve patient quality of life, our novel nanoparticle technology holds promise for addressing some of the most pressing healthcare challenges of our time. #Theranostics #PrecisionMedicine #Nanotechnology #Innovation #Healthcare #Research #Science

🚨 Liver models to test new drugs based on 2D cell culture of primary hepatocytes and the use of experimental animal models are slow, costly, and have significant biases. 🎯 With our new Nuclis I+D project funded by ACCIÓ, we aim to revolutionize liver research by creating cutting-edge in vitro models using diverse human cells via bio-printing, promising highly accurate preclinical insights to propel clinical advancements in drug development These models, created in collaboration with the Institute for Institute for Bioengineering of Catalonia (IBEC), have several advantages 👇🏽 Follow along to discover the advancements of the project! #bioprinting #cellculture #drugscreening #liverdisease #BeCytesBiotechnologies

Advanced approaches to immuno-oncology research are being galvanized with new humanized mouse models and 3D co-culture techniques to better understand therapeutic intervention. However, understanding the best model is critical to building successful IO studies with interpretable readouts. In this webinar, we will provide insights into immuno-oncology ex vivo assays and in vivo models to help improve the accuracy of preclinical studies. Register to attend live or on-demand to learn more about how to navigate Translational IO Models: https://hubs.li/Q02hfXvW0

⏰Don’t miss our January 18 Workshop on Strategic Model Selection in Immuno-oncology. Reserve your seat now!👉 https://lnkd.in/eEGkHRzd You’ll walk away with a deeper understanding of; ✅Criteria for selecting the right immuno-oncology models ✅The wide variety of animal models available to meet your research needs ✅The pros and cons of various animal systems ✅How to set up your studies for success

More and more scientists from Academia and Pharma industries are using new approach methods (NAMs) to fast-forward the development of the next generation of therapeutics. This is why I am looking forward to next Wednesday, I will be attending with Meilin Berkhoff a great event, to connect experts with better tools for their translational research. I am particularly curious to hear more about how Organoid-based models are already impacting the 3Rs (Replace, Reduce, and Refine) initiative. Exciting to see that Adult Stem Cell-derived Organoids will also be a key element of the day. https://lnkd.in/e2S-m5V2 #Mimetas #Organoids #OrganonaChip #OoaC

Today's #EmployeeSpotlight is Senior Scientist of RNA Discovery Biology, Dahyana Arias Escayola! In July, Dahyana spoke at the 3rd annual mRNA-Based Therapeutics Summit. Her presentation, Smart mRNA: Designing & Developing the Future of Programmable & Switchable mRNA Tools, discussed the therapeutic potential of mRNA circuits in oncology. Thanks Dahyana! #BioTechNews #BioTech #mRNAResearch #mRNA #mRNATherapies